Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients

Recruiting now

Conditions studied: Cancer, NGS, Tumor, RARE DISEASE

In brief

As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing. The SONCO (Sequencing Oncology Cohort) project combines their medical and economic evaluations into a single national cohort. Its objective is to assess the impact of genomic sequencing on care pathways and treatment recommendations by collecting indicators related to quality, turnaround time, and patient information. Clinical data are gathered from molecular tumor board reports (via SPICE and HYGEN) and from hospital medical records. This cohort is intended to support public health decision-making and help anticipate the organization of future genomic platforms.

Key facts

Study ID

NCT07147465

Run by

Assistance Publique - Hôpitaux de Paris

People needed

3149

Starts

2025-07-01

Expected to finish

2026-09-30

Last updated by the study team

2025-08-29

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with cancer and referred for high-throughput sequencing
• Sequencing pre-indication validated: Patients for whom the pre-indication for sequencing the genome, exome, and RNA has been validated by the upstream RCP (Multidisciplinary Tumor Board) since January 1, 2021.
• Consent for data reuse: Patients who have agreed to the reuse of their medical and genomic data for research purposes and have not opposed this use.

You may not qualify if…

• Opposition to data reuse, unvalidated upstream RCP

Where it is running

• Centre Leon Berard — Lyon, France (enrolling)
• HOPITAL AP-HP Cochin — Paris, France (enrolling)
• APHP Hôtel Dieu URC Economie de la sante /URC ECO — Paris, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.